OUR PRODUCTS

HELPING
MEDICINES
DO MORE

Pushing healthcare forward requires us to propel medicines to their full potential. We make possible what others consider impossible. Take a look at our product portfolio to see what the right mix of technology and heart can accomplish.

RYANODEX® (dantrolene sodium) for injectable suspension

RYANODEX® is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.1

DOCETAXEL INJECTION (non-alcohol formula)

Docetaxel Injection is a microtubule inhibitor indicated for3:
Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer
Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN

BENDEKA® (bendamustine hydrochloride) injection

BENDEKA® is an alkylating drug indicated for the treatment of patients with2:

  • Chronic lymphocytic leukemia (CLL). Efficacy relative to first-line therapies other than chlorambucil has not been established
  • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen
ARGATROBAN

Argatroban Injection is a direct thrombin inhibitor indicated4:

  • For prophylaxis or treatment of thrombosis in adult patients with heparin-induced thrombocytopenia (HIT)
  • As an anticoagulant in adult patients with or at risk of HIT undergoing percutaneous coronary intervention (PCI)

WHERE OTHERS SEE A
STOPPING POINT,
WE SEE UNTAPPED
POTENTIAL.

We believe that making the best end product
starts at the beginning. This is why we use our
3-step process of reinvention to see products
through from start to finish.

1

Identify medicines that can benefit from second generation advancements

2

Improve products by determining the technology requirements to address unmet needs

3

Impact patients’ lives with improved medicines brought to market primarily through the 505(b)(2) regulatory pathway

Through a fully integrated commercial team, we have the flexibility to market our products with or without a partner.

REFERENCES:

  1. RYANODEX (dantrolene sodium) for injectable suspension [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2016.
  2. BENDEKA (bendamustine hydrochloride) injection [package insert]. North Wales, PA: Teva Pharmaceuticals USA, Inc.; 2017.
  3. DOCETAXEL INJECTION (non-alcohol formula) [package insert]. Woodcliff Lake, NJ: Eagle Pharmaceuticals, Inc.; 2016.
  4. Argatroban Injection [package insert]. Parsippany, NJ: The Medicines Company; 2016.